Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation	Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Active, not recruiting	Phase 2	2026-05-04		NCT05491811

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Central People's Hospital of Zhanjiang	7
Fifth Affiliated Hospital, Sun Yat-Sen University	41
First Affiliated Hospital of Wenzhou Medical University	117
First People's Hospital of Foshan	44
Guangdong Provincial Agricultural Reclamation Central Hospital	1
Guangzhou Institute of Respiratory Disease	16
Hebei Medical University Fourth Hospital	83
Second Affiliated Hospital, Zhejiang University, School of Medicine	561
Shenyang Chest Hospital	1
Sun Yat-sen University	606
The First Affiliated Hospital with Nanjing Medical University	319
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	319
West China Hospital	359
Yuebei People's Hospital	14
Yunnan Cancer Hospital	46

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Sun Yat-Sen University Cancer Center	Guangzhou	China	113